PSFG
RPRX icon

Park Square Financial Group’s Royalty Pharma RPRX Stock Holding History

Park Square Financial Group’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.67K Sell
119
-45
-27% -$2.34K 0.06% 103
2026
Q1 		$7.87K Buy
+164
New +$7.18K 0.06% 108
2025
Q4 		– Sell
-433
Closed -$15.3K – 291
2025
Q3 		$15.3K Buy
+433
New +$15.7K 0.07% 122

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Park Square Financial Group's RPRX Position: Q2 2026 in Review

Park Square Financial Group reduced its Royalty Pharma (RPRX) stake by 27% in Q2 2026, selling an estimated $2.34K and leaving 119 shares worth $6.67K. The position accounts for 0.06% of the portfolio, ranked #103.

Park Square Financial Group first reported a position in RPRX in Q3 2025 and has held it in 3 quarters since. The position peaked at $15.3K in Q3 2025. 641 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Park Square Financial Group held 119 shares of Royalty Pharma worth $6.67K as of Q2 2026.
  • Park Square Financial Group sold 45 Royalty Pharma shares in Q2 2026, an estimated $2.34K.
  • Royalty Pharma made up 0.06% of Park Square Financial Group's portfolio in Q2 2026, its #103 holding.
  • Park Square Financial Group first reported a position in Royalty Pharma in Q3 2025 and has held it in 3 quarters since.
  • Park Square Financial Group's Royalty Pharma position peaked at $15.3K in Q3 2025.
  • 641 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Park Square Financial Group's 13F filing for Q2 2026, filed 31 Jul 2026.